Presentations, Webcasts & Media

Displaying 1 to 1 of 1 files.

Media and News

  The Wall Street Transcript - Interview with Robert B Jones (351.1 KiB) - added November 23, 2011
Reprinted from November 14, 2011 issue of The Wall Street Transcript.

Webcasts

BioCentury Publications, Inc. NewsMakers in the Biotech Industry Conference
Millennium Broadway Hotel
New York, NY
Friday, October 21, 2011 3:00 PM EDT
Presenter: Bob Jones, Chief Executive Officer

To listen to the audio webcast: Click Here. A replay of the webcast will be available for 30 days after the event.

Displaying 1 to 4 of 4 files.

Presentations

  BE Study AP-ADD-100 (769.0 KiB) - added October 19, 2011
Bioequivalence of Immediate-Release Oxycodone With Aversion® Technology (IRO-A), IRO-A With Niacin, and a Commercially Available Oxycodone.
Study Purpose: To evaluate bioequivalence by comparing the pharmacokinetic (PK) characteristics of IRO-A with those of another branded, commercially available immediate-release oxycodone HCl (IRO) (Roxicodone®, Xanodyne Pharmaceuticals, Inc., Newport, KY, USA), and IRO-A with niacin.

  Phase III Study AP-ADF-105 (687.8 KiB) - added May 7, 2009
Acurox® Tablets (Oxycodone HCL/Niacin) for the Treatment of Acute, Moderate to Severe Pain Following Bunionectomy Surgery in Adult Patients
Study Purpose: Evaluate safety and efficacy in relief of moderate to severe pain

  Phase II Study AP-ADF-111 (962.3 KiB) - added April 30, 2009
A Phase II, Single-Center, Randomized, Double-Blind Assessment of the Subjective Effectes of Acurox® (Oxycodone HCL/Niacin) Tablets in Volunteers With a History of Opioid Abuse
Study Purpose: Evaluate abuse liability of oxycodone HCl/niacin versus oxycodone HCl alone

  Phase II Study AP-ADF-102 (280.5 KiB) - added April 21, 2009
Evaluate for Flushing, Safety & Tolerability of Niacin (N) in Combination with 40mg of Oxycodone (O)
Study Purpose: Evaluate relative dislike of oxycodone HCl/niacin versus oxycodone HCl alone